Rhumbline Advisers Aerie Pharmaceuticals Inc Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$6.37 - $15.23 $77,070 - $184,267	12,099 Added 17.93%	79,568 $1.2 Million
Q2 2022 Aug 11, 2022	BUY	$4.95 - $9.16 $88,535 - $163,835	17,886 Added 36.07%	67,469 $506,000
Q1 2022 May 12, 2022	BUY	$5.64 - $9.8 $6,525 - $11,338	1,157 Added 2.39%	49,583 $451,000
Q4 2021 Feb 10, 2022	BUY	$7.02 - $13.33 $3,460 - $6,571	493 Added 1.03%	48,426 $340,000
Q3 2021 Nov 12, 2021	BUY	$11.32 - $16.63 $23,239 - $34,141	2,053 Added 4.47%	47,933 $546,000
Q2 2021 Aug 05, 2021	SELL	$15.16 - $18.97 $4,578 - $5,728	-302 Reduced 0.65%	45,880 $735,000
Q1 2021 May 06, 2021	SELL	$13.12 - $20.9 $61,244 - $97,561	-4,668 Reduced 9.18%	46,182 $825,000
Q4 2020 Feb 10, 2021	BUY	$9.12 - $14.49 $12,275 - $19,503	1,346 Added 2.72%	50,850 $687,000
Q3 2020 Nov 12, 2020	SELL	$10.46 - $14.46 $144,839 - $200,227	-13,847 Reduced 21.86%	49,504 $583,000
Q2 2020 Aug 13, 2020	BUY	$12.0 - $16.13 $43,116 - $57,955	3,593 Added 6.01%	63,351 $935,000
Q1 2020 May 06, 2020	SELL	$11.84 - $25.52 $10,064 - $21,692	-850 Reduced 1.4%	59,758 $807,000
Q4 2019 Feb 05, 2020	BUY	$17.72 - $25.1 $42,067 - $59,587	2,374 Added 4.08%	60,608 $1.47 Million
Q3 2019 Oct 23, 2019	BUY	$18.41 - $28.0 $12,205 - $18,564	663 Added 1.15%	58,234 $1.12 Million
Q2 2019 Aug 14, 2019	BUY	$28.97 - $48.21 $303,026 - $504,276	10,460 Added 22.2%	57,571 $1.7 Million
Q1 2019 May 01, 2019	SELL	$36.32 - $49.25 $12,966 - $17,582	-357 Reduced 0.75%	47,111 $2.24 Million
Q4 2018 Jan 31, 2019	BUY	$33.0 - $60.04 $497,442 - $905,042	15,074 Added 46.53%	47,468 $1.71 Million
Q3 2018 Nov 07, 2018	SELL	$56.15 - $73.9 $124,933 - $164,427	-2,225 Reduced 6.43%	32,394 $1.99 Million
Q2 2018 Aug 06, 2018	BUY	$47.85 - $70.45 $135,271 - $199,162	2,827 Added 8.89%	34,619 $2.34 Million
Q1 2018 May 02, 2018	SELL	$51.15 - $61.0 $2,148 - $2,562	-42 Reduced 0.13%	31,792 $1.73 Million
Q4 2017 Feb 09, 2018	SELL	$50.85 - $65.1 $244,639 - $313,196	-4,811 Reduced 13.13%	31,834 $1.9 Million
Q3 2017 Nov 06, 2017	BUY	$48.6 - $60.1 $1.78 Million - $2.2 Million	36,645	36,645 $1.78 Million

Others Institutions Holding AERI

# of Institutions

Shares Held

2.4M

Call Options Held

Put Options Held

View Full List

About AERIE PHARMACEUTICALS INC

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

More about AERI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account